Form 4: Vir Biotechnology Director Janet Napolitano Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Director Janet Napolitano of Vir Biotechnology sold 12,190 shares of common stock on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 9, 2024, Janet Napolitano, a director of Vir Biotechnology, Inc., sold 12,190 shares of common stock.
- The sales were executed under a Rule 10b5-1 trading plan adopted on June 10, 2024.
- The shares were sold at a weighted average price of $7.7959.
- Following the transaction, Napolitano directly owns 11,616 shares of Vir Biotechnology.
- The price range for the shares sold was between $7.49 and $7.97.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to a stock sale by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
Sales by insiders are common and can be for a variety of personal financial reasons. The use of a 10b5-1 trading plan suggests the insider is selling shares in a pre-planned manner to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| June 10, 2024 | Date the reporting person adopted a Rule 10b5-1 trading plan |
| September 9, 2024 | Date of the transaction (stock sale) |
| September 10, 2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.